Pluristem Receives Israeli Ministry of Health Approval to Initiate Phase II Study Using PLacental eXpanded
October 02, 2013 at 05:49 AM EDT
Pluristem Therapeutics (NASDAQ: PSTI ) announced today that the Israeli Ministry of Health has approved the company's request to initiate a Phase II study using its PLacental eXpanded (PLX) cells in the treatment of Intermittent Claudication (IC), a subset of peripheral artery disease (PAD). This approval is part of
